# US Montelukast API Market

> US Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.22%
- **2024:** $ 212.1 Million
- **2025:** $ 235.9 Million
- **2035:** $ 683.43 Million
- **Key Players:** Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (NL), Cipla Limited (IN), Aurobindo Pharma (IN), Hikma Pharmaceuticals (GB), Sandoz (CH), Zydus Cadila (IN)

**Report ID:** MRFR/HC/51550-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-montelukast-api-market-53311

---

## Market Summary

## **US Montelukast API Market Overview**

As per MRFR analysis, the US Montelukast API Market Size was estimated at 189 (USD Million) in 2023. The US Montelukast API Market Industry is expected to grow from 211.5(USD Million) in 2024 to 684.5 (USD Million) by 2035. The US Montelukast API Market CAGR (growth rate) is expected to be around 11.268% during the forecast period (2025 - 2035).

### **Key US Montelukast API Market Trends Highlighted**

The rise in the prevalence of asthma and allergic rhinitis, which are chronic conditions that affect a substantial fraction of the population, is the primary factor driving the US Montelukast API market. A constant demand for effective treatments is prompted by the fact that asthma affects millions of Americans, as per the Centers for Disease Control and Prevention (CDC).

The leukotriene receptor antagonist, Montelukast, is essential in the management of these conditions, which has resulted in a consistent increase in its API market. In addition, the medication's affordability and accessibility have been enhanced by the proliferation of generic versions in the aftermath of its exclusivity loss. Public health initiatives are providing support for the increasing emphasis on asthma education and awareness programs, emphasizing the urgent need for effective therapeutics.

Opportunities are emerging as the healthcare landscape in the United States is transitioning toward personalized medicine, which is facilitating the development of customized asthma management strategies. Formulations or delivery mechanisms of Montelukast have the potential to be innovative, which could improve patient adherence and outcomes.

Further promoting the development of novel applications of Montelukast beyond its traditional use, collaborations between pharmaceutical companies and research institutions can investigate synergies with other therapeutic agents or therapies. Regulatory compliance and quality assurance have become increasingly important in the API manufacturing process, as evidenced by recent trends.

The US Food and Drug Administration (FDA) is actively involved in the enforcement of rigorous manufacturing guidelines to guarantee that Montelukast APIs adhere to the highest criteria for safety and efficacy. Manufacturers are being compelled to invest in technological advancements and quality improvements as a result of this regulatory scrutiny, which is thus improving the overall competitiveness of the US market. In the United States, the dynamic nature of this market is further reflected by the ongoing research into the long-term effects of Montelukast and the continuous exploration of alternative therapeutics.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **US Montelukast API Market Drivers**

### **Rising Prevalence of Allergies and Respiratory Disorders**

The increasing prevalence of allergies and respiratory disorders, particularly in the United States, is a significant driver for the US Montelukast API Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 26 million Americans have asthma, which represents a substantial population that can benefit from Montelukast, a leukotriene receptor antagonist widely prescribed for asthma and allergic rhinitis.

The American Academy of Allergy, Asthma, and Immunology reports that allergies affect over 50 million Americans annually, leading to increased healthcare costs and a growing demand for effective treatment options. This increasing patient population is expected to drive growth in the Montelukast market, as healthcare providers seek therapeutic options that effectively manage symptoms and reduce asthma attacks. The focus on improving patient quality of life and minimizing healthcare burdens underscores the expansion of the US Montelukast API Market, with robust demand anticipated in the next decade.

### **Increase in Generic Drug Availability**

The rise in the availability of generic drugs significantly influences the growth of the US Montelukast API Market Industry. The expiration of patents for branded medications has paved the way for generic versions, making treatments more accessible and affordable for patients. The U.S. Food and Drug Administration (FDA) reported that the availability of generic drugs leads to a price reduction of approximately 80% post-patent expiration.

With a broader patient base opting for cost-effective medications, the increased market penetration of generic Montelukast is expected to considerably expand market revenue and volume. This transition aligns with the U.S. government’s initiative to lower prescription drug costs, further propelling the demand for generic APIs and enhancing the overall landscape of the Montelukast market.

### **Growing Focus on Preventive Healthcare**

There is a shifting paradigm towards preventive healthcare among the American populace, which directly impacts the US Montelukast API Market Industry. A report by the National Center for Health Statistics notes that preventive services utilization is on the rise, with 83% of U.S. adults receiving at least one preventive healthcare service in their lifetime.

This trend indicates an Rises in proactive management of respiratory conditions, as patients seek to minimize the risk of acute attacks through early interventions, including medication like Montelukast. Additionally, healthcare policy changes favoring preventative approaches reinforce the demand for products that mitigate chronic conditions. The growth in awareness and education around preventative care reflects a promising future for the Montelukast market, as healthcare providers prioritize strategies that improve respiratory health outcomes.

## **US Montelukast API Market Segment Insights**

### **Montelukast API Market Application Insights**

The Application segment of the US [Montelukast API Market](../../../reports/montelukast-api-market-7886) showcases important insights reflecting the growing demand for various treatments aimed at managing respiratory and allergic conditions. The market has been characterized by an increasing focus on chronic respiratory diseases, particularly asthma, which affects millions of individuals in the US.

According to health organizations, asthma prevalence has been consistently rising, calling for effective treatment options like Montelukast, which is recognized for its role in controlling symptoms and preventing exacerbations. Additionally, allergic rhinitis represents a significant portion of the market as it is a common condition impacting daily life, leading to substantial healthcare-seeking behavior. The treatment for bronchospasm, primarily triggered by specific allergens, further enlarges the scope of Montelukast API applications, making it a valuable option for patients dealing with this acute respiratory issue.

One of the key driving factors behind this segment's growth is the increasing awareness regarding the potential health impacts of untreated allergies and asthma. Along with this, the rise in environmental pollutants and allergens in urban settings is propelling the need for effective medications. The Montelukast API is also being utilized for managing conditions like urticaria, which is a significant source of discomfort due to its itching and skin lesions.

Therefore, its role in providing symptomatic relief cannot be overstated, making it a vital component of treatment regimens for patients suffering from various allergic conditions. Emerging research continues to unveil new therapeutic opportunities while also addressing potential challenges, mainly in terms of the growing resistance to certain treatments. As patient awareness rises and healthcare professionals advocate for comprehensive treatment strategies, competition within the market may intensify.

Ideally, there are opportunities for innovation, especially geared towards combination therapies that can better address multifaceted symptoms in patients. Overall, the Application segment of the US Montelukast API Market not only plays a pivotal role in improving patient care but also contributes to the broader market dynamics by catering to an increasingly diverse patient demographic seeking effective treatments for asthma, allergic rhinitis, bronchospasm, urticaria, and other related conditions, promising a steady growth trajectory in the coming years.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **US Montelukast API Market Key Players and Competitive Insights**

The US Montelukast API Market is characterized by a competitive landscape that includes a variety of players vying for market share through strategic initiatives, product development, and innovation. Montelukast, primarily used as an anti-allergic medication and as a part of asthma management, has seen consistent demand due to its effectiveness and growing patient awareness regarding respiratory conditions.

The market dynamics are influenced by several factors, including regulatory developments, pricing pressures, and the entry of generics, which further intensifies competition. Additionally, companies are increasingly focusing on research and development to enhance their product offerings and cater to specific patient demographics. Collaboration and partnerships for distribution and technological advancements are also pivotal for players looking to enhance their market presence in this vital therapeutic area.

Teva Pharmaceutical stands out in the US Montelukast API Market due to its robust portfolio and extensive distribution network. The company has made significant investments in production capabilities and quality assurance processes, making it a reliable supplier for generic formulations of Montelukast. Teva's strengths lie in its established presence and brand recognition among healthcare providers and patients. Their commitment to addressing unmet medical needs, along with competitive pricing strategies, allows them to maintain a strong foothold in the market.

Additionally, continuous improvements in manufacturing efficiencies and a focus on regulatory compliance further bolster Teva's ability to compete effectively in this landscape.

Amgen also plays a crucial role in the US Montelukast API Market with its focus on biotechnology and innovative therapeutic solutions. It has established a reputation for delivering high-quality pharmaceutical products. It is known for its strong emphasis on research and development, allowing the company to dive deeper into specialized treatment options. Amgen's market presence is amplified through strategic mergers and acquisitions that have expanded its capabilities and product pipeline. The company's strengths include a strong financial foundation, strategic collaborations, and a diversified product portfolio that incorporates biologics and traditional pharmaceuticals.

Their expertise in targeting specific patient needs positions them uniquely within the market, making them a formidable competitor in the Montelukast space and ensuring their continued relevance in the evolving landscape of respiratory therapies within the US.

### **Key Companies in the US Montelukast API Market Include**

### **US Montelukast API Market Industry Developments**

The US Montelukast API Market has seen significant activity recently, with continued interest from major pharmaceutical players such as Teva Pharmaceutical, Amgen, and Merck amidst ongoing regulatory scrutiny. In August 2023, the FDA acknowledged the importance of monitoring safety profiles for Montelukast, pushing companies to engage in more rigorous post-marketing studies, which may impact their operational strategies.

In terms of mergers and acquisitions, Dr. Reddy's Laboratories completed the acquisition of a generic medication portfolio, including Montelukast, in July 2023, targeting expansion in the respiratory segment. Growth in market valuation is evident, especially as companies like Sun Pharmaceutical and Lupin Pharmaceuticals continue to innovate and expand manufacturing capabilities.

Additionally, the rising prevalence of asthma and allergic rhinitis in the US generates a steady demand for Montelukast, highlighting its critical role in public health. Over the last few years, Zydus Cadila has also strengthened its position in the Montelukast API sector, leveraging advancements in biotechnology to enhance product offerings. The market remains dynamic as these companies navigate regulatory changes and seek to meet the evolving needs of healthcare providers and patients in the US.

## **Montelukast API Market Segmentation Insights**

### **Montelukast API Market Application Outlook**

## Market Drivers

### Cost-Effectiveness of Montelukast

The montelukast api market benefits from the cost-effectiveness of montelukast as a treatment option for asthma and allergic rhinitis. With healthcare costs continuously rising, patients and providers are increasingly looking for affordable yet effective medications. Montelukast, being available in generic forms, offers a more economical choice compared to other treatments. The average retail price for montelukast is significantly lower than many branded alternatives, making it accessible to a broader patient population. This affordability is particularly crucial in the US, where healthcare expenses can be a barrier to treatment. As a result, the montelukast api market is likely to see sustained demand as patients prioritize cost-effective solutions for managing their respiratory conditions.

### Rising Awareness of Asthma Management

The montelukast market is benefiting from rising awareness regarding asthma management among patients and healthcare providers. Educational campaigns and resources provided by organizations such as the American Lung Association have increased understanding of asthma and its treatment options. This heightened awareness encourages patients to seek appropriate medical care and adhere to prescribed treatments, including montelukast. As more individuals recognize the importance of effective asthma management, the demand for montelukast is likely to rise. Additionally, healthcare providers are increasingly recommending montelukast as a first-line treatment, further solidifying its position in the montelukast api market. This trend suggests a positive outlook for the market as awareness continues to grow.

### Growing Focus on Preventive Healthcare

The montelukast market is influenced by the growing focus on preventive healthcare in the US. As healthcare systems shift towards preventive measures, there is an increasing emphasis on managing chronic conditions like asthma before they escalate. Montelukast is often prescribed as a preventive treatment, helping to reduce the frequency and severity of asthma attacks. This proactive approach aligns with public health initiatives aimed at reducing healthcare costs and improving patient outcomes. The US government has been promoting preventive healthcare strategies, which may further bolster the demand for montelukast. Consequently, the montelukast api market is poised for growth as more patients seek preventive solutions to manage their respiratory health.

### Advancements in Pharmaceutical Research

The montelukast market is positively impacted by advancements in pharmaceutical research and development. Ongoing studies are exploring the efficacy of montelukast in various patient populations, including children and those with comorbid conditions. Research indicates that montelukast may have additional benefits beyond asthma management, such as its potential role in treating exercise-induced bronchoconstriction. These findings could expand the therapeutic applications of montelukast, leading to increased prescriptions and market growth. Furthermore, as pharmaceutical companies invest in research to enhance drug formulations and delivery methods, the montelukast api market may see innovations that improve patient compliance and outcomes. This dynamic environment suggests a promising future for the montelukast api market.

### Increasing Prevalence of Allergic Conditions

The montelukast market is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis in the US. According to the CDC, approximately 25 million Americans suffer from asthma, which translates to about 8% of the population. This increasing incidence drives demand for effective treatments, including montelukast, which is widely prescribed for managing these conditions. As healthcare providers seek to address the needs of patients with respiratory issues, the montelukast api market is likely to expand. Furthermore, the growing awareness of the importance of managing allergies effectively contributes to the market's upward trajectory, as patients and healthcare professionals alike recognize the benefits of montelukast in improving quality of life.

## Future Outlook

The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at 11.22% CAGR from 2025 to 2035, driven by increasing asthma prevalence and rising healthcare expenditure.

**New opportunities:**

- Development of specialized montelukast formulations for pediatric use.
- Expansion into emerging markets with tailored pricing strategies.
- Partnerships with telehealth platforms for remote patient management solutions.

By 2035, the montelukast API market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing)

The US montelukast api market demonstrates a distinctive segmentation wherein Asthma holds the largest share. The segment for Asthma significantly outperforms its counterparts, especially in patient prescriptions and treatment plans among various demographics. Following Asthma, Allergic Rhinitis emerges as an essential segment, capitalizing on the rising incidence of allergic conditions. Other segments like Bronchospasm and Urticaria, while contributing to the market, occupy a smaller share proportion.

In recent years, the demand for montelukast api products focused on Asthma has seen considerable growth, driven by increasing awareness and prevalence of respiratory diseases. The Allergic Rhinitis segment is expanding rapidly, attributed to increased environmental allergens and enhanced diagnosis rates. Overall, innovation in drug formulations and a greater emphasis on preventive healthcare are key trends shaping these segments market trajectory.

Asthma (Dominant) vs. Allergic Rhinitis (Emerging)

Asthma has established itself as the dominant segment in the US montelukast api market due to its high prevalence among both adults and children, making it a focal point for pharmaceutical interventions. Numerous studies and clinical applications focus on optimal treatment methodologies, positioning companies to meet increasing patient needs efficiently. In contrast, Allergic Rhinitis is emerging rapidly, propelled by a growing number of patients seeking relief from seasonal and perennial allergies. This segment is gaining traction through targeted marketing campaigns and the introduction of innovative treatment protocols that enhance patient adherence. As research into allergic conditions advances, both segments are expected to remain crucial to the overall landscape of the US montelukast api market.

## Competitive Benchmarking

The montelukast API market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Merck & Co (US), Teva Pharmaceutical Industries (IL), and Mylan N.V. (NL) are actively pursuing strategies that enhance their market positioning. Merck & Co (US) has focused on strengthening its research and development capabilities, aiming to innovate within the respiratory therapeutic area. Meanwhile, Teva Pharmaceutical Industries (IL) has been expanding its manufacturing footprint in the US, which appears to be a strategic move to optimize supply chain efficiencies and meet growing demand. Mylan N.V. (NL) is also enhancing its operational focus on digital transformation, which may provide a competitive edge in terms of customer engagement and operational agility.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to respond swiftly to market demands. The montelukast API market is moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive innovation and set industry standards that smaller competitors may struggle to match.

In October  Merck & Co (US) announced a collaboration with a leading technology firm to integrate AI into its drug development processes. This strategic move is likely to enhance Merck's ability to streamline research timelines and improve the efficacy of its product offerings, thereby reinforcing its competitive position in the market.

In September  Teva Pharmaceutical Industries (IL) launched a new initiative aimed at increasing the sustainability of its manufacturing processes. This initiative not only aligns with global sustainability trends but also positions Teva as a responsible player in the pharmaceutical industry, potentially attracting environmentally conscious consumers and stakeholders.

In August  Mylan N.V. (NL) entered into a strategic partnership with a digital health company to develop a comprehensive patient management platform. This collaboration is expected to enhance patient adherence to montelukast therapy, thereby improving health outcomes and solidifying Mylan's market presence through innovative patient engagement strategies.

As of November  the montelukast API market is witnessing trends that emphasize digitalization, sustainability, and the integration of advanced technologies such as AI. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to leverage each other's strengths. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is becoming evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and adapt to evolving market demands, rather than solely competing on price.

## Recent News & Developments

The US Montelukast API Market has seen significant activity recently, with continued interest from major pharmaceutical players such as Teva Pharmaceutical, Amgen, and Merck amidst ongoing regulatory scrutiny. In August 2023, the FDA acknowledged the importance of monitoring safety profiles for Montelukast, pushing companies to engage in more rigorous post-marketing studies, which may impact their operational strategies.

In terms of mergers and acquisitions, Dr. Reddy's Laboratories completed the acquisition of a generic medication portfolio, including Montelukast, in July 2023, targeting expansion in the respiratory segment. Growth in market valuation is evident, especially as companies like Sun Pharmaceutical and Lupin Pharmaceuticals continue to innovate and expand manufacturing capabilities.

Additionally, the rising prevalence of asthma and allergic rhinitis in the US generates a steady demand for Montelukast, highlighting its critical role in public health. Over the last few years, Zydus Cadila has also strengthened its position in the Montelukast API sector, leveraging advancements in biotechnology to enhance product offerings. The market remains dynamic as these companies navigate regulatory changes and seek to meet the evolving needs of healthcare providers and patients in the US.

## Report Scope

| MARKET SIZE 2024 | 212.1(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 235.9(USD Million) |
| MARKET SIZE 2035 | 683.43(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.22% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (NL), Cipla Limited (IN), Aurobindo Pharma (IN), Hikma Pharmaceuticals (GB), Sandoz (CH), Zydus Cadila (IN) |
| Segments Covered | Application |
| Key Market Opportunities | Growing demand for montelukast API in respiratory therapies presents significant market opportunities. |
| Key Market Dynamics | Regulatory changes and competitive pressures drive innovation in the montelukast active pharmaceutical ingredient market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US montelukast API market in 2024?**
A: The market valuation of the US montelukast API market was $212.1 Million in 2024.

**Q: What is the projected market valuation for the US montelukast API market by 2035?**
A: The projected market valuation for the US montelukast API market is $683.43 Million by 2035.

**Q: What is the expected CAGR for the US montelukast API market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US montelukast API market during the forecast period 2025 - 2035 is 11.22%.

**Q: Which companies are considered key players in the US montelukast API market?**
A: Key players in the US montelukast API market include Merck & Co, Teva Pharmaceutical Industries, Mylan N.V., Cipla Limited, Aurobindo Pharma, Hikma Pharmaceuticals, Sandoz, and Zydus Cadila.

**Q: What are the main application segments of the US montelukast API market?**
A: The main application segments of the US montelukast API market include Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, and Others.

**Q: What was the market size for the asthma segment in the US montelukast API market in 2024?**
A: The market size for the asthma segment in the US montelukast API market was between $80.0 Million and $250.0 Million in 2024.

**Q: How does the allergic rhinitis segment perform in the US montelukast API market?**
A: The allergic rhinitis segment in the US montelukast API market had a valuation ranging from $50.0 Million to $150.0 Million in 2024.

**Q: What is the projected growth for the bronchospasm segment in the US montelukast API market?**
A: The bronchospasm segment is expected to grow, with a valuation between $30.0 Million and $100.0 Million in 2024.

**Q: What was the valuation range for the urticaria segment in the US montelukast API market in 2024?**
A: The valuation range for the urticaria segment in the US montelukast API market was between $20.0 Million and $60.0 Million in 2024.

**Q: What is the potential market size for the 'Others' segment in the US montelukast API market?**
A: The potential market size for the 'Others' segment in the US montelukast API market was between $32.1 Million and $123.43 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-montelukast-api-market-53311*